Avelumab

AssetAlso called MSB-0010682, MSB0010718C, Bavencio

Blocks PD-L1 to restore immune responses against tumor cells.

Stage
Approved
Modality
Antibody
Target
CD274
10
Indications
259
Trials
1
Developer

Approved by the FDA on Mar 23, 2017 (BLA761049). 3 approvals stand. FDA

Indications

10
  • Advanced Renal Cell Carcinoma

    Approved, FDA

  • Locally advanced or metastatic urothelial carcinoma

    Approved, FDA

  • Metastatic Merkel Cell Carcinoma

    Approved, FDA

7 more

In the full profile

  • Target and mechanism2
  • Owner and partners2
  • Trials259
  • Evidence for its targets3
  • Competitors12
  • Signals15

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets